Sabinsa's founder, Chairman, and Managing Director, Dr Muhammed Majeed, has announced the publication of a new book. This latest is entitled "Reductive Metabolites of Curcuminoids."
Over the last two decades curcuminoids have been the most intensively studied herbal constituents, and Sabinsa has been at the forefront of much of the research.
"The central theme of the book is to emphasise that the effects of curcumin observed in animal models and in human trials are the aggregate benefits of curcumin and the reductive metabolites of curcuminoids," explained Majeed.
Authored by Majeed with N. Kalyanam, PhD, President of R&D, and other members of the Sami-Sabinsa Group's technical staff, this book details the transformation of curcumin into its metabolites inside the body, and the significance of major metabolites. The book compiles the pharmacological activities of the four reduced curcuminoids.
The book also reviews the scientific evidence on the effects of microbiota on what has been called "poor bioavailablity," and discusses the unmistakable role of microbiota in transforming curcumin into its major pharmacologically-potent reductive metabolite, Tetrahydrocurcumin.
Curcuminoids have pleiotropic pharmacological effects and they are also known to be extensively metabolised. One class of metabolites includes the phase I metabolites of curcumin arising out of reductive metabolism of the double bonds and carbonyl groups in curcumin. In addition, gut microbiota also reduces curcumin to the reductive metabolites.
The Sabinsa staff will have copies of the book at their Booth 4131 at SupplySide West in Las Vegas, NV 17–18 October, 2019.
